CIN-109

Financing brings total funds raised to $176M to advance diverse portfolio of high-impact medicines and expand efforts to additional high unmet needs Current portfolio of CinCos include two clinical-stage obesity therapeutics, two Phase 2 gastrointestinal programs and several pre-clinical programs CINCINNATI--(BUSINESS WIRE)-- CinRx Pharma, a hub-and-spoke biotech accelerating high-impact medicines, today announced the closing of a $73 million financing, bringing the total funds raised to $176 million. Participants in the round include prior investors comprised of industry insiders and high-net-worth individuals. To date, CinRx has launched five companies (“CinCos”) focused primarily on cardiovascular, metabolic and gastrointestinal conditions. In addition to its company creation function, CinRx has forged several CINergy partnerships with existing companies. CinRx plans to use the funds to advance development of its existing portfolio programs and assets to expand in key areas of high unmet medical need. “Our early financings totaling $103 million supported the construction and progression of our seven-company portfolio. Notably, this included the formation, advancement and exit of CinCor Pharma ahead of its $1.8 billion acquisition, underscoring the success of our incredibly effective team and validation of our efficient business model,” said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. “With this infusion of capital, we will continue rapid advancement of existing programs and replicate our proven asset selection process to identify and accelerate more promising new programs with high potential to impact patients’ quality of life.” CinRx’s portfolio of CinCos are managed by a lean team of scientific, technical and drug development experts with decades of experience treating patients and supporting thousands of clinical development programs. Each CinCo was created through a rigorous asset selection process to identify novel therapies with the potential to address significant unmet medical needs and meaningfully reduce disease burden for patients. CinCor Pharma was created to advance baxdrostat (CIN-107), a highly selective, oral small molecule inhibitor of aldosterone synthase for the treatment of hypertension and other cardiorenal conditions from a license agreement with Roche in 2019. CinRx led the clinical design and execution of baxdrostat, and was responsible for CinCor’s successful Series A and Series B financings to fund its early development through its $194 million IPO in 2022. In early 2023, CinCor was acquired by AstraZeneca in a deal worth $1.3 billion upfront and an additional $500 million in biobucks. CinFina Pharma is developing a pipeline of four therapies, in-licensed from Janssen Pharmaceuticals, aimed at providing safe, tolerable and durable options for treating obesity. In March 2024, CinFina announced the dosing of the first patients in a Phase 1 trial of CIN-110, a PYY analog. Upcoming milestones include initiation of a Phase 2 study evaluating CIN-109, a novel GDF-15 molecule focusing on body composition and lean body mass preservation, with and without semaglutide. Additional preclinical development is ongoing to support Investigational New Drug (IND) application submissions for CIN-209 and CIN-210, which are both dual-agonists utilizing GLP-1 therapy in combination with the aforementioned mechanisms of action. CinDome Pharma is developing deudomperidone (CIN-102) as a potential safe, chronic treatment for gastroparesis. Deudomperidone is a novel formulation of a well-known dopamine D2/D3 agonist, domperidone. In May 2023, CinDome presented encouraging QT study data at the 2023 Digestive Disease Week (DDW) Conference. CinDome recently raised $40 million in a Series B financing from Perceptive Advisors and CinRx, and is actively enrolling the Phase 2 envision3D study for adults with diabetic gastroparesis, expected to read out in 2025. CinPhloro Pharma is progressing CIN-103, a small molecule for the long-term management of irritable bowel syndrome with diarrhea (IBS-D). CIN-103 is a pulsatile-release formulation of phloroglucinol, an approved therapy in select countries outside of the U.S., modified for sustained exposure and less frequent dosing. In February 2024, CinPhloro dosed the first patients in the Phase 2 enviva study to evaluate the safety, efficacy and tolerability of CIN-103 for IBS-D. CinPhloro is actively enrolling the enviva study, which is expected to complete in 2025. About CinRx Pharma: CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team. Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life. CinRx Pharma is headquartered in Cincinnati, Ohio. For more information, please visit or follow the company on X and LinkedIn.

Scientific advisory board members include Caroline Apovian, M.D., Louis Aronne, M.D., FACP, Samuel Klein, M.D., Donna Ryan, M.D. and Randy Seeley, Ph.D. CINCINNATI--(BUSINESS WIRE)-- CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline. The members of CinFina’s SAB include renowned metabolic and obesity academic researchers and expert clinicians. The newly formed SAB will help guide the development of CinFina’s promising pipeline of versatile medicines including a long-acting growth/differentiation factor-15 (GDF-15) analog and a peptide YY (PYY) analog, both as monotherapy options and chemically combined with a GLP-1 receptor agonist. The pipeline includes CIN-109 and CIN-110, as well as additional early-stage candidates. CIN-109 is a first-in-class GDF-15 analog that has recently completed its multiple ascending dose (MAD) study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity following administration of multiple subcutaneous doses in otherwise healthy subjects with obesity. CIN-110 is a potent and selective PYY3-36 analog, for which an Investigational New Drug (IND) Application is being filed with the U.S. FDA with plans for human clinical trials in Q1 2024. “This impressive group of key opinion leaders in the metabolic space will be integral to the future success of our CinFina program as we look to fill the need for differentiated, safe, effective and tolerable treatments for obesity and weight management,” said Dr. Jon Isaacsohn, Founder and Chief Executive Officer at CinRx Pharma. “The formation of this SAB is timed with important development milestones for our monotherapy programs, and I believe we can make strong progress to help patients and physicians and address the global health crisis of obesity.” The members of CinFina’s SAB are as follows: Caroline Apovian, M.D. is a professor of medicine at Harvard Medical School, and co-director at the Center for Weight Management and Wellness, at Brigham & Women’s Hospital. One of the world’s premier weight management experts, Dr. Apovian has distinguished herself as a leading researcher, healthcare provider, teacher, and The New York Times bestselling author. Nationally, she is one of the founding creators of the American Board of Obesity. Her research interests are weight change and its effects on adipose tissue metabolism and inflammation, obesity and cardiovascular disease, resolution of type 2 diabetes and cardiovascular disease in the bariatric surgery population, disparities in the treatment of obesity in underserved populations, and novel pharmacotherapeutic agents for the treatment of obesity. Louis Aronne, M.D., FACP is a professor of metabolic research at Weill-Cornell Medical College, and director of the Center for Weight Management and Metabolic Clinical Research. Additionally, Dr. Aronne is founder and CEO of BMIQ, a weight control program that is delivered by health care providers to their patients during office visits. Vice-chairman of the board of the American Board of Obesity Medicine, he has authored more than 60 papers and book chapters on obesity and edited the National Institutes of Health Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. He served as a consultant to the VA Weight Management/Physical Activity Executive Council in the development of the MOVE program, the nation’s largest medically based weight control program. Samuel Klein, M.D. is a professor of medicine and nutritional science at Washington University in St. Louis, and chief of the Division of Nutritional Science and Obesity Medicine. Dr. Klein is past president of the North American Association for the Study of Obesity and the American Society for Clinical Nutrition. He was inaugural chair of the Integrative Physiology of Obesity and Diabetes NIH study section. His research activities focus on understanding the mechanisms responsible for metabolic abnormalities associated with obesity and the therapeutic effects of weight loss. Donna Ryan, M.D. is a professor emerita at Pennington Biomedical​. Dr. Ryan was principal investigator for the U.S. Department of Defense for a series of awards which targeted military nutrition approaches to improve soldier readiness and performance. Her research interests included lifestyle intervention and diet for weight loss, and she was an investigator on NIH studies including POUNDS Lost, Look AHEAD, DPP, and DASH. She was the co-chair of the SELECT Steering Committee and consults with many companies developing medication and commercial medical interventions for obesity. Randy Seeley, Ph.D. is a director at the Michigan Nutrition Obesity Research Center. Dr. Seeley’s scientific work has focused on the actions of various peripheral hormones in the central nervous systems (CNS) that serve to regulate food intake, body weight and the levels of circulating fuels. In particular, he has focused upon the numerous hypothalamic and gastrointestinal (GI) peptides and their associated receptors that influence both energy intake as well as peripheral metabolic processes, with a focus on developing new treatment strategies for both obesity and diabetes. About CinFina Pharma: CinFina, a CinRx portfolio company, is expanding the treatment of obesity and its associated comorbidities with a pipeline of therapeutic candidates designed to be safe, tolerable, and durable to help people lose weight and keep it off to improve their overall health. CinFina’s four therapeutic candidates are naturally occurring peptides engineered for prolonged activity which send signals in the body to control insulin secretion or feelings of satiety. About CinRx Pharma: CinRx is a mosaic of biotechnology companies supported by a dedicated funding mechanism designed to improve drug development success and accelerate transformational new medicines to patients. By integrating our deep scientific, clinical, and operational expertise with a thoughtful portfolio model, we establish the optimal development trajectory – a drug development superhighway. The company’s experienced team ensures high-potential medicines are financially and operationally championed with the most efficient route from the lab to the patient. For more information, please visit or follow the company on X and LinkedIn. View source version on businesswire.com: Contacts Source: CinRx Pharma View this news release online at: